Market Intelligence, Clinical Progress, and High-Purity Reagents for Targeted Protein Degradation (TPD) Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DCAF5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DCAF5 Recombinant Protein (WD40 Domain / Full Length) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for biophysical binding assays. |
View DCAF5 Products |
| Gene Delivery | DCAF5 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and target degradation validation. |
View DCAF5 Products |
| Benchmark Ab | Anti-DCAF5 Recombinant Antibody High-affinity recombinant positive control for Western Blot and IP assays. |
View DCAF5 Products |
| Validator | DCAF5 siRNA Set For target knockdown verification in cellular degradation assays. |
View DCAF5 Products |
| Related Target A | DDB1 Core adapter protein of the CUL4-RING ligase (CRL4) complex, essential for DCAF5 recruitment and stability. |
View DDB1 Products |
| Related Target B | CUL4A Scaffold protein of the CRL4-DCAF5 complex, critical for reconstituting in vitro ubiquitination assays. |
View CUL4A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| DCAF5-DDB1 complex stability in vitro | Co-expressed DCAF5/DDB1 complex proteins available with >95% purity and verified stoichiometry. |
| Subfamily off-target counter-screening | Comprehensive DCAF family protein panel (DCAF1, DCAF11, DCAF15) strictly verified by Mass Spectrometry. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive control expression constructs included. |
| False Positives in Degradation Assays | Validated siRNA pools included for precise target knockdown and specificity verification. |
Live DCAF5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DCAF5 therapeutics is intensifying, with major players shifting focus from traditional E3 ligases (like CRBN and VHL) to novel substrate receptors within the CUL4-RING ligase (CRL4) family. DCAF5 (DDB1- and CUL4-associated factor 5) contains a WD40-repeat domain that serves as a versatile platform for recruiting neo-substrates. As first-generation PROTACs and molecular glues face clinical resistance or tissue-limitation challenges, the next wave of R&D is targeting DCAF5 to expand the druggable proteome and achieve tissue-specific protein degradation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Molecular Glues | Monte Rosa Therapeutics, Bristol Myers Squibb | Hematological Malignancies, Solid Tumors | Ternary Complex Validation (Need high-purity DCAF5/DDB1 complex proteins) |
| PROTACs | Arvinas, Kymera Therapeutics | Oncology, Autoimmune Diseases | Ubiquitination Kinetics (Need active CUL4-DDB1-DCAF5 recombinant machinery) |
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Viral Infections, Refractory Cancers | Selectivity Assay (Need DCAF family counter-screening panel) |